Is ATHX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,621 people get ATHX articles and Market Currents by email alert.

Get email alerts on ATHX »

HEADLINES:

Athersys Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 14
Does Cell Therapy Hold The Key To Treating Stroke?
PropThink • Mon, May 13 • 11 Comments
Speculative Bio Stocks For Investors
Stock Investor • Wed, May 8 • 4 Comments
Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance
Ryan's View • Fri, May 3 • 5 Comments
Athersys Has Some Promise, But Controversy And Doubt Remain
Alberto Savrieno • Thu, May 2 • 25 Comments
StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Company
BlackbirdAnalytics • Thu, May 2 • 13 Comments
Athersys to Present at 12th Annual Needham Healthcare Conference

GlobeNewswire (Apr 25, 2013)
Stem Cells: Dreamers, Fools, And The Valley Of Death
EnhydrisPECorp • Thu, Apr 25 • 24 Comments
Athersys, Inc: The Facts
BioStocksElite • Sat, Apr 20 • 22 Comments
Trading Athersys: Risks And Rewards
BlackbirdAnalytics • Fri, Apr 19 • 61 Comments
Athersys to Host First Quarter 2013 Financial Results Call

GlobeNewswire (Apr 18, 2013)
Athersys Announces Authorization of Stem Cell Clinical Trial for Stroke in the United Kingdom

GlobeNewswire (Apr 17, 2013)
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
Athersys: Valuation
BioStocksElite • Fri, Apr 12 • 5 Comments
Athersys to Present at Regen Med Investor Day 2013 in New York

GlobeNewswire (Apr 11, 2013)
Publications Demonstrate Relevance of MultiStem(R) for Autoimmune Disease, Transplantation and Vascular Disease

GlobeNewswire (Apr 10, 2013)
Athersys, Inc. Has Blockbuster Potential
BioStocksElite • Wed, Mar 27 • 14 Comments
Opexa: A Significant Growth Opportunity For Short-Term Traders And Long-Term Investors
Scott Matusow • Tue, Mar 26 • 29 Comments
Phase II Trials Will Be Pivotal For These Stem Cell Companies
Ryan's View • Wed, Mar 20 • 11 Comments
A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships
Craig Keolanui • Mon, Mar 18 • 2 Comments

Athersys: A Significantly Undervalued Stem Cell Company Approaching Key Catalysts
BlackbirdAnalytics • Wed, Jan 30 • 29 Comments

Athersys Has Some Promise, But Controversy And Doubt Remain
Alberto Savrieno • Thu, May 2 • 25 Comments
Athersys, Inc: The Facts
BioStocksElite • Sat, Apr 20 • 22 Comments
Trading Athersys: Risks And Rewards
BlackbirdAnalytics • Fri, Apr 19 • 61 Comments
Athersys: Valuation
BioStocksElite • Fri, Apr 12 • 5 Comments
Athersys, Inc. Has Blockbuster Potential
BioStocksElite • Wed, Mar 27 • 14 Comments
Athersys' MultiStem Platform Tempts Big Pharma And Investors
Chemistfrog • Mon, Mar 4 • 16 Comments
Athersys: The Coming Year Will Define MultiStem, Its Adult Stem Cell Product
Smith On Stocks • Fri, Feb 8 • 19 Comments
A Candid Conversation With Athersys CEO Gil Van Bokkelen
BlackbirdAnalytics • Thu, Jan 31 • 11 Comments
Athersys: A Significantly Undervalued Stem Cell Company Approaching Key Catalysts
BlackbirdAnalytics • Wed, Jan 30 • 29 Comments
Stem Cell Therapy Companies: Underappreciated Outperformers
Ryan's View • Tue, Jan 29 • 11 Comments
Athersys: Upcoming Short-Term Catalyst With Promising Longer Term Potential
Scott Matusow • Tue, Jan 22 • 7 Comments
Athersys: An Undervalued Spec Company With High Potential
bsiflingtrades • Thu, Jan 10 • 26 Comments
Weak Trading In Athersys Following Share Dilution
Brian L. Wilson • Sun, Jan 6 • 21 Comments
Athersys Should Gain At Least 50%
BuySellShort • Fri, Nov 30, 2012 • 15 Comments
Athersys Shares Poised To Move Higher
Wall Street Titan • Thu, Dec 1, 2011 • 10 Comments
Athersys MultiStem PI Data For Acute Myocardial Infarction
Henry McCusker • Mon, Nov 7, 2011 • 2 Comments
Athersys Q2 Loss Is Slight Improvement Over Previous Year
Henry McCusker • Thu, Aug 11, 2011
Athersys Releases Impressive 12 Month Heart Attack Data for MultiStem
Wall Street Titan • Fri, Jun 10, 2011 • 6 Comments
Athersys Releases Encouraging Results for Single Dose Arm of MultiStem
Wall Street Titan • Thu, May 26, 2011
Athersys: Grossly Undervalued Given Its Potential
Wall Street Titan • Sun, May 1, 2011 • 2 Comments

Does Cell Therapy Hold The Key To Treating Stroke?
PropThink • Mon, May 13 • 11 Comments
Speculative Bio Stocks For Investors
Stock Investor • Wed, May 8 • 4 Comments
Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance
Ryan's View • Fri, May 3 • 5 Comments
StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Company
BlackbirdAnalytics • Thu, May 2 • 13 Comments
Stem Cells: Dreamers, Fools, And The Valley Of Death
EnhydrisPECorp • Thu, Apr 25 • 24 Comments
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
Opexa: A Significant Growth Opportunity For Short-Term Traders And Long-Term Investors
Scott Matusow • Tue, Mar 26 • 29 Comments
Phase II Trials Will Be Pivotal For These Stem Cell Companies
Ryan's View • Wed, Mar 20 • 11 Comments
A Study Of 3 Biotechs - A Story Of Hope, Potential And Partnerships
Craig Keolanui • Mon, Mar 18 • 2 Comments
Valuing Amarantus - Where Financial Reality Meets Scientific Hope
Jason Napodano • Mon, Mar 11 • 12 Comments
Predicting Biotech Stock Moves Based On Consensus Picks By Legendary Fund Managers
GuruFundPicks • Tue, Feb 5 • 3 Comments
4 Speculative Biotech Stocks To Consider
BuySellShort • Thu, Jan 31 • 28 Comments
Small-Pharma Watch List: Week Of January 28th
Chemistfrog • Mon, Jan 28 • 11 Comments
Stem Cell Stocks To Consider: Aastrom, Athersys, StemCells And Neuralstem
BuySellShort • Wed, Jan 16 • 6 Comments
Looking Beyond The JPM Global Healthcare Conference: More Biotech Than Meets The Eye
Nouvelle Asset Management • Tue, Jan 8 • 14 Comments
3 Small-Cap Healthcare Companies That Have Bottomed Out In October
Jorge Aura • Mon, Oct 15, 2012 • 14 Comments
4 Biotechs That Just Got Mauled By Bears
Brian L. Wilson • Wed, Oct 10, 2012 • 11 Comments
Biotechs Treating Incurable Disease Warrant Early Look
Troy Bayer • Fri, Sep 14, 2012 • 8 Comments
Pfizer's Pipeline Could Push Stock 20% Higher By 2014
IncomeHunter • Tue, Sep 11, 2012 • 2 Comments
The Next Big Growth Sector In Health Care: Stem Cell Therapy
Troy Bayer • Tue, Sep 4, 2012 • 13 Comments

Athersys Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, May 14
Athersys Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
Athersys Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012
Athersys Management Discusses Q2 2012 Results - Earnings Call Transcript
Mon, Aug 13, 2012
Athersys, Inc. Q3 2008 Earnings Call Transcript
Fri, Nov 28, 2008
Athersys, Inc. Q2 2008 Earnings Call Transcript
Sat, Sep 20, 2008

Athersys to Present at 12th Annual Needham Healthcare Conference

GlobeNewswire (Apr 25, 2013)
Athersys to Host First Quarter 2013 Financial Results Call

GlobeNewswire (Apr 18, 2013)
Athersys Announces Authorization of Stem Cell Clinical Trial for Stroke in the United Kingdom

GlobeNewswire (Apr 17, 2013)
Athersys to Present at Regen Med Investor Day 2013 in New York

GlobeNewswire (Apr 11, 2013)
Publications Demonstrate Relevance of MultiStem(R) for Autoimmune Disease, Transplantation and Vascular Disease

GlobeNewswire (Apr 10, 2013)
Athersys Reports Fourth Quarter and 2012 Annual Results

GlobeNewswire (Mar 12, 2013)
Athersys to Host Fourth Quarter and Year-End 2012 Financial Results Call

GlobeNewswire (Feb 25, 2013)
Athersys Announces Adjournment of Special Meeting Date

GlobeNewswire (Feb 21, 2013)
Athersys to Present at New York Stem Cell Summit '13

GlobeNewswire (Feb 13, 2013)
Athersys to Present at BIO CEO & Investor Conference

GlobeNewswire (Feb 11, 2013)
Athersys Files Shelf Registration to Replace Expiring S-3 Registration Statement

GlobeNewswire (Jan 11, 2013)
Athersys to Present at Biotech Showcase(TM) 2013

GlobeNewswire (Jan 7, 2013)
Athersys to Present at Piper Jaffray 24th Annual Healthcare Conference

GlobeNewswire (Nov 19, 2012)
Athersys Named to Deloitte's 2012 Technology Fast 500(TM)

GlobeNewswire (Nov 15, 2012)
Athersys Reports Third Quarter 2012 Results

GlobeNewswire (Nov 8, 2012)
Athersys Announces Exercise of Overallotment Option

GlobeNewswire (Nov 6, 2012)
Athersys Receives Cell Therapy Manufacturing Award

GlobeNewswire (Nov 1, 2012)
Athersys to Host Third Quarter 2012 Financial Results Call

GlobeNewswire (Oct 26, 2012)
Athersys Prices Public Offering of Common Stock

GlobeNewswire (Oct 26, 2012)
Athersys Presents New Data Demonstrating Potential Benefits From MultiStem After Spinal Cord Injury

GlobeNewswire (Oct 15, 2012)

ATHX vs. ETF Alternatives

Company Description

Currently, there's no company description for ATHX.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, May 14, 6:07 PM More on Athersys (ATHX): Q1 misses on both EPS and revenue as total sales reflected a $2.4M decrease in Pfizer contract revenues. Net losses more than doubled over the period, as fair value of warrant liabilities resulted in an expense of $2.6M due to the re-pricing and increases in share price. Shares -3.3% AH. Comment! [Healthcare, On the Move, Earnings]
Tuesday, May 14, 4:29 PM Athersys (ATHX): Q1 EPS loss of $0.18 misses by $0.07. Revenue or $326K misses by $1.254M (may not be comparable). (PR). Shares +1% AH. Comment! [Healthcare, Breaking News, Earnings]
Tuesday, March 12, 4:31 PM Athersys (ATHX): Q4 EPS of -$0.07 beats by $0.03. Revenue of $2.3M beats by $0.6M. (PR) 4 Comments [Earnings, Breaking News, Healthcare]
Tuesday, January 22, 3:40 PM Athersys (ATHX +6.4%) gets a boost today, possibly from an upbeat Seeking Alpha piece that touts its strong pipeline. ATHX is a clinical stage biopharmaceutical company with a number of potential catalysts in its portfolio. Its most advanced programs are in the area of regenerative medicine using its stem cell therapy called MultiStem for the treatment of ischemic stroke. StemCells (STEM -2.3%) slips, possibly on the same article, which says it's in pre-clinical trials for the same indication, but its product isn't as advanced as that of ATHX. 1 Comment [Healthcare, On the Move]
Tuesday, October 9, 2012, 9:10 AM Premarket gainers: RSH +11%. EMXX +10%. QCOR +7%. NAVB +6%.
Losers: EW -17%. ATHX -14%. OC -7%. NFLX -7%. ALU -5%. 3 Comments [On the Move]
Friday, October 5, 2012, 9:17 AM Regenerative-medicine firm Athersys (ATHX) up 9.2% premarket as Maxim Group raises its price target on the biopharma to $6.00 from $3.00. Shares closed yesterday at $1.31. 2 Comments [Healthcare, On the Move, Breaking News]
Friday, October 5, 2012, 9:10 AM Premarket gainers: PPP +26%. ATHX +9%.
Losers: CTIC -28%. ZNGA -20%. VRNG -14%. ABR -5%. Comment! [On the Move]
Friday, May 11, 2012, 9:15 AM Premarket gainers: ARNA +93%. GV +45.5%. ATHX +15%. AVG +12%. ZOOM +9%. MDR +9%. SOL +8%. NVDA +8%.
Losers: RNDY -11%. PBTH -11%. DAR -9%. JPM -8.5%. SNE -8%. Comment! [On the Move]
Friday, April 27, 2012, 8:53 AM Athersys (ATHX) +8.9% premarket after announcing its met with the FDA to discuss results of its recent clinical trial involving the administration of its MultiStem treatment for patients with leukemia or other conditions that place them at risk of graft vs. host disease. Comment! [Healthcare, On the Move]
Friday, February 3, 2012, 11:05 AM Shares of Athersys (ATHX +3.2%) bounce higher after the firm presents positive data on its MultiStem heart stroke treatment. The firm believes the stroke market represents a commercial opportunity of more than $15B annually. Comment! [On the Move, Healthcare]
Wednesday, February 1, 2012, 11:36 AM Microcap biotech research firm Athersys (ATHX +8%) jumps after disclosing $3.6M in grant funding to further advance its MultiStem product research and development programs and other cell therapy platforms. Comment! [Healthcare, On the Move]
Tuesday, August 24, 2010, 9:51 AM Stem cell stocks are under pressure after yesterday's ruling by a federal judge that blocks federal funding for research involving human embryonic stem cells. STEM -6.3%, GERN -3.8%, CYTX -3.6%, ASTM -3.3%, ATHX -2.8%, SGMO -1.4%, OSIR -0.6%. 2 Comments
Monday, December 21, 2009, 9:48 AM Athersys (ATHX) +200% after inking a deal with Pfizer (PFE) to develop and market its experimental stem cell therapy MultiStem. Pfizer will pay $6M up front, fund the drug's R&D, and pay up to $105M on milestones. Comment!

tomfalbo
LONG $TSRX $ATHX - bought big on every dip - take profits accordingly - large core holdings - 2013/14 big years
Apr 2, 11:09 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

richardod
?started biotech 12M- $GALE should be good but moving slowly $EYCT (UP60%) $PSTI now back. buying $ATHX do not see more winners suggestions?
Mar 28, 5:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
Add a reply...

140 characters

toegar2000
Stock shows a lot of potential. I'm long and have been buying since $1.15.Comfortable position and holding till mid 2014. $ATHX Strong Buy
Mar 21, 10:10 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
I thought "pump and dump" works like the price goes up a bit, sell, then price tanks. so what are these picks of mine then? $ATHX @ $1.25
Feb 5, 9:57 AM
Reply (4)

• !Report Abuse
View all 4 replies
Scott Matusow: nope i think longterm its a winner
Feb 5, 12:37 PM
• !Report Abuse
tomfalbo: agree Scott... I am generally long this guy, but closed my .99 to 1.65 lot, and re-buying after this bear pull-back
Feb 5, 5:05 PM
• !Report Abuse
Add a reply...

140 characters

skywola
Diluting ATHX will make it crash and burn . . . then that will be the time to buy.
10/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
$$ Just posted: 6 High-Growth Biotech Stocks Analysts Rate As Buys http://bit.ly/KZ6RCp $BONE $AFFY $ATHX $ALXN $ACOR $BMRN @ZetaKap
5/18/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: Bacterin is definitely a Buy! Now if they could only do a better job of informing investors of how truly ground breaking their tech is.
Mar 8, 5:37 AM
• !Report Abuse
Add a reply...

140 characters

munchkin
ATHX - coming back to life...
2/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

munchkin
ATHX oversold @ close - will it deliver tomorrow?
2/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Watch NutriSystem (NTRI), Athersys (ATHX), Hi-Tech Pharmacal (HITK), & Mercer (MERC), some of the few stocks that rose yesterday.
12/13/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Wall Street Titan
Athersys (ATHX) CEO purchasing shares. Clinical results due this QTR. Stem cell sector in play with CEPH $2B commitment to Mesoblast. BUY
4/5/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

richardod
?started biotech 12M- $GALE should be good but moving slowly $EYCT (UP60%) $PSTI now back. buying $ATHX do not see more winners suggestions?
Mar 28, 5:55 PM
Reply (2)

• !Report Abuse
View all 2 replies
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
pagreen1966: Try $INO.
Apr 16, 6:38 AM
• !Report Abuse
Add a reply...

140 characters

ZetaKap
$$ Just posted: 6 High-Growth Biotech Stocks Analysts Rate As Buys http://bit.ly/KZ6RCp $BONE $AFFY $ATHX $ALXN $ACOR $BMRN @ZetaKap
5/18/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Webb: Bacterin is definitely a Buy! Now if they could only do a better job of informing investors of how truly ground breaking their tech is.
Mar 8, 5:37 AM
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I thought "pump and dump" works like the price goes up a bit, sell, then price tanks. so what are these picks of mine then? $ATHX @ $1.25
Feb 5, 9:57 AM
Reply (4)

• !Report Abuse
View all 4 replies
Scott Matusow: nope i think longterm its a winner
Feb 5, 12:37 PM
• !Report Abuse
tomfalbo: agree Scott... I am generally long this guy, but closed my .99 to 1.65 lot, and re-buying after this bear pull-back
Feb 5, 5:05 PM
• !Report Abuse
Add a reply...

140 characters

ATHX Athersys, Inc.

ATHX

Athersys, Inc.